- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | AROA BIOSURGERY LIMITED: Notification regarding unquoted securities - ARX | - | ASX | ||
| 28.07. | AROA BIOSURGERY LIMITED: Commercial Leadership Appointments | - | ASX | ||
| 24.07. | AROA BIOSURGERY LIMITED: Notice of Annual General Meeting/Proxy Form | - | ASX | ||
| 14.07. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | - | ASX | ||
| 14.07. | AROA BIOSURGERY LIMITED: Symphony - Outpatient Reimbursement Update | - | ASX | ||
| 09.07. | AROA BIOSURGERY LIMITED: Resignation of CFO and Joint Company Secretary | - | ASX | ||
| 30.06. | AROA BIOSURGERY LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 30.06. | AROA BIOSURGERY LIMITED: Annual Report to Shareholders | - | ASX | ||
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 29.06. | AROA BIOSURGERY LIMITED: Change of Director's Interest Notice - JD | - | ASX | ||
| 24.06. | AROA BIOSURGERY LIMITED: Notice of AGM Date and Director Nomination Closing Date | - | ASX | ||
| 27.05. | AROA BIOSURGERY LIMITED: Change in substantial holding | - | ASX | ||
| 26.05. | Biocurious: Aroa brings a touch of 'magic' to the US$3 billion woundcare sector | 1 | Stockhead | ||
| 26.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation - Correction | - | ASX | ||
| 26.05. | Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance | 2 | smallcaps.com.au | ||
| 26.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation | - | ASX | ||
| 26.05. | AROA BIOSURGERY LIMITED: FY26 Appendix 4E and Full Year Results | - | ASX | ||
| 19.05. | AROA BIOSURGERY LIMITED: Notification of Full Year Results Webinar | - | ASX | ||
| 30.04. | Health Check: Investors say "not baa-d" as Aroa smashes earnings expectations out of the paddock | 3 | Stockhead | ||
| 30.04. | AROA BIOSURGERY LIMITED: ARX FY26 Preliminary Results | - | ASX | ||
| 10.04. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,70 | +3,33 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| EVOTEC | 3,464 | +0,93 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen | |
| MODERNA | 51,36 | +0,37 % | Moderna startet Phase-1-Studie mit Ebola-Impfstoffkandidat | Moderna hat eine Phase-1-Studie mit seinem Impfstoffkandidaten mRNA-1469 gegen das Bundibugyo-Ebolavirus (BDBV) begonnen. Nach der Genehmigung durch die kanadische Gesundheitsbehörde wurden in Kanada... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,490 | +1,22 % | Heidelberg Pharma: Was die Halbjahreszahlen über die Zukunft verraten | Bei Biotech-Unternehmen sagt eine einzelne Zahlenreihe selten alles, doch manchmal markiert sie einen Wendepunkt. Bei der Heidelberg Pharma AG (ISIN: DE000A11QVV0) könnte der Mitte Juli vorgelegte Halbjahresbericht... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,580 | +1,05 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| BIOMARIN PHARMACEUTICAL | 55,16 | +6,90 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| IBIO | 1,264 | +3,27 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| VAXART | 0,600 | 0,00 % | Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding | ||
| ARBUTUS BIOPHARMA | 3,980 | -0,50 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 23,360 | -0,26 % | Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer | ||
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,168 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| TRAWS PHARMA | 0,543 | +2,05 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen |
AROA BIOSURGERY LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.